Document Detail


The cost of treating ribavirin-induced anemia in hepatitis C: the impact of using recombinant human erythropoietin.
MedLine Citation:
PMID:  17559739     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: Ribavirin-induced anemia (RIA) is a common adverse effect of chronic hepatitis C treatment. Studies have shown that the use of epoetin decreases the need for ribavirin dose reduction or discontinuation. The primary objective was to calculate the incremental cost of treating hepatitis C in those without versus with RIA, using either the strategy of ribavirin dose reduction/discontinuation or epoetin. The secondary objective was to calculate the incremental cost of using epoetin versus no epoetin to treat RIA, per ribavirin dose reduction/discontinuation averted. METHODS: Estimates from the literature and decision-analytic techniques were used to model treatment patterns and estimate the cost of managing RIA in genotype 1, 2, and 3 subjects. Sensitivity analyses were used to address uncertainty. RESULTS: Clinically significant RIA, a reduction in hemoglobin of > or = 2 g/dL (1.2 mmol/L), developed in 72% of patients in observational studies. The incremental cost of treating chronic hepatitis C decreased when employing the strategy of ribavirindose reduction/discontinuation to treat RIA, and increased by 5.7% (genotype 1) or 34.4% (genotype 2 or 3), when using epoetin. Using one-way sensitivity analyses, the cost of using epoetin per ribavirin dose reduction/discontinuation averted was $39,579-$52,023. Generalizability may be limited to settings in which a similar proportion of patients develop RIA. CONCLUSIONS: The proportional cost of treating hepatitis C when using epoetin to treat RIA is significant in genotype 2 or 3 patients. The cost of using epoetin per ribavirin dose reduction/discontinuation averted is substantial in patients with genotypes 1, 2, or 3; and varies with the probability of response to epoetin. These findings suggest that additional studies are warranted that will determine the effect of epoetin on treatment outcomes and its role as supportive therapy in patients with RIA.
Authors:
E B Devine; J T Cross; K V Kowdley; S D Sullivan
Related Documents :
12139149 - Surgical drainage of primary iliopsoas abscess--safe and cost-effective treatment.
19903649 - Costs and rehabilitation use of stroke survivors: a retrospective study of medicare ben...
19916959 - Anti-tnf and crohn's disease: when should we stop?
20028199 - The cost effectiveness and budget impact of natalizumab for formulary inclusion.
7633969 - The cost-effectiveness of treatment of short occlusive lesions in the femoropopliteal a...
19064859 - Resource use and costs associated with diabetic macular edema in elderly persons.
17622789 - Clevudine therapy for 24 weeks further reduced serum hepatitis b virus dna levels and i...
19877069 - Classification, presentation, and initial treatment of wegener's granulomatosis in chil...
23338109 - The analgesic effect of nitroglycerin added to lidocaine on quality of intravenous regi...
Publication Detail:
Type:  Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural     Date:  2007-05-17
Journal Detail:
Title:  Current medical research and opinion     Volume:  23     ISSN:  1473-4877     ISO Abbreviation:  Curr Med Res Opin     Publication Date:  2007 Jun 
Date Detail:
Created Date:  2008-04-23     Completed Date:  2008-07-09     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0351014     Medline TA:  Curr Med Res Opin     Country:  England    
Other Details:
Languages:  eng     Pagination:  1463-72     Citation Subset:  IM    
Affiliation:
University of Washington Department of Pharmacy, Seattle, WA 98195-7630, USA. bdevine@u.washington.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Algorithms
Anemia / chemically induced,  drug therapy*,  economics*
Antiviral Agents / adverse effects,  therapeutic use
Cohort Studies
Cost-Benefit Analysis
Erythropoietin, Recombinant / economics*,  therapeutic use*
Genotype
Health Care Costs
Health Resources / economics,  utilization
Hepatitis C / drug therapy*,  genetics
Humans
Models, Theoretical
Ribavirin / adverse effects*,  therapeutic use
Treatment Outcome
Grant Support
ID/Acronym/Agency:
K24DK02957/DK/NIDDK NIH HHS
Chemical
Reg. No./Substance:
0/Antiviral Agents; 0/Erythropoietin, Recombinant; 36791-04-5/Ribavirin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The complexity of medication regimens and test ordering for patients with diabetes from 1995 to 2003...
Next Document:  Will insomnia treatments produce overall cost savings to commercial managed-care plans? A predictive...